Chemical Namedinutuximab
Dosage FormInjection (intravenous; 17.5 mg/5 mL)
Drug ClassMonoclonal antibodies
CompanyUnited Therapeutics
Approval Year2015


  • Indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Last updated on 10/27/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Unituxin (dinutuximab) Prescribing Information2017United Therapeutics Corp., Silver Spring, MD